.Booster Pharmaceutical: Shareholder Li Bin of the holding subsidiary intends to transfer 2.00% of equity for 55,600 yuan.

According to a notice from Buchang Pharmaceutical, the company held the fifty-fourth meeting of the fifth board of directors on August 11, 2026, during which it approved the proposal on the equity transfer of its holding subsidiary. The shareholder Li Bin of the company's holding subsidiary Hangzhou Buchang Jianxin intends to transfer 2.00% of his shares in Hangzhou Buchang Jianxin to Yi Cui for a price of 55,600 RMB. After the completion of this transfer, the company's holding ratio in Hangzhou Buchang Jianxin will remain unchanged at 90.00%, and Li Bin's remaining capital contribution obligation of 66,700 RMB will be assumed by the transferee Yi Cui. This transaction does not constitute a related party transaction, nor does it constitute a significant asset restructuring as defined by the Measures for the Administration of Major Asset Restructuring of Listed Companies, and does not require submission for shareholder approval.